Navigation Links
Spherix Announces Institutional Investors Purchase $5.25 Million of Convertible Preferred Stock and Warrants
Date:10/7/2010

BETHESDA, Md., Oct. 7 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX), an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that it has entered into agreements to sell $5.25 million of shares of its Series B Convertible Preferred Stock and warrants to purchase shares of its common stock in a registered offering to institutional investors.  Each share of Series B Convertible Preferred Stock is convertible at the option of the holder, at any time during its existence, into approximately 800 shares of common stock at a conversion price of $1.25 per share of common stock for a total of approximately 4.2 million common shares.

In connection with the offering, the investors received warrants to purchase up to 2.1 million shares of common stock.  The warrants have an exercise price of $1.50 per warrant share, and are exercisable immediately upon issuance and terminate 60 months after the date of issuance.

The Company intends to use the net proceeds from the offering to continue the development of D-tagatose for diabetes and triglycerides, as well as for general corporate purposes.

Shares of the Series B Convertible Preferred Stock will receive dividends in the same amount as any dividends declared and paid on shares of common stock and have no voting rights on general corporate matters.

The closing of the offering is expected to occur on October 13, 2010 or earlier, at which time the Company will receive the cash proceeds and deliver the securities.

Rodman & Renshaw, LLC, a wholly-owned subsidiary of Rodman & Renshaw Capital Group, Inc. (Nasdaq: RODM), ac
'/>"/>

SOURCE Spherix Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Spherix Completes Enrollment in NEET, a Phase 3 Clinical Trial Evaluating an Oral Drug for Type 2 Diabetes
2. Spherix to Present at Annual OneMedPlace Finance Forum and at EBD Biotech Showcase in San Francisco
3. Spherix Reports Third Quarter 2009 Earnings
4. Spherix Announces Positive Phase 2 Study Results
5. Spherix Reports First Quarter 2009 Earnings
6. Spherix Elects New Independent Director, and Elects Chairman of the Board
7. Spherix Postpones 2009 Annual Shareholders Meeting to Share Interim Diabetes Clinical Trial Data
8. Spherix Expands Phase 3 Naturlose Diabetes Trial Outside of the U.S.
9. Spherix D-tagatose to be Supplied by Inalco SpA
10. Growth Achieved in Spherixs Health Sciences Consulting Business
11. Spherix Reports Second Quarter Earnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... 2015  New product launches are critical events for ... educating thought leaders about new products, Medical Affairs is ... well a new therapy performs at launch. ... consulting leader Best Practices, LLC, critical aspects of launch ... are early stage thought leader (TL) interaction, successful TL ...
(Date:7/2/2015)... 2015 According to a new market ... Stimulation, Spinal Cord Stimulation, Transcranial Magnetic Stimulation), Application (Depression, Parkinson,s, ... 2020", published by MarketsandMarkets, the global Neuromodulation Market is estimated ... $6.20 Billion by 2020, at a CAGR of 11.2% during ... 4 market data T ables and ...
(Date:7/2/2015)... , July 2, 2015 Numotion,s Board ... Officer announced that Tamas Feitel has joined ... joins Numotion after a highly successful 18 year career ... roles driving strategy, profitability, and productivity to result in ... recent position was Chief Financial Officer for GE Healthcare ...
Breaking Medicine Technology:Medical Affairs Role in Thought Leader Education is Key Success Factor for New Product Launches in the Pharmaceutical Industry 2Neuromodulation Market Worth $6.20 Billion by 2020 2Neuromodulation Market Worth $6.20 Billion by 2020 3Neuromodulation Market Worth $6.20 Billion by 2020 4Numotion Names Tamas Feitel Chief Financial Officer 2
... Vancouver Radiologists, P.C., a full-spectrum provider of diagnostic ... greater Vancouver, Wash., and Portland, Ore., areas, has ... use of MedInformatix Inc.,s Radiology Information System ... three-location practice to control from a single platform ...
... CareFusion (NYSE: CFN ), ... Officer Dwight Winstead will leave the company on June 30. ... separated from Cardinal Health on Sept. 1, 2009, during which ... for the company,s business segments. He joined Cardinal Health in ...
Cached Medicine Technology:Vancouver Radiologists Leverages MedInformatix RIS as Practice Management Hub, Data Mining Tool to Improve Workflow and Enhance Efficiencies 2Vancouver Radiologists Leverages MedInformatix RIS as Practice Management Hub, Data Mining Tool to Improve Workflow and Enhance Efficiencies 3Vancouver Radiologists Leverages MedInformatix RIS as Practice Management Hub, Data Mining Tool to Improve Workflow and Enhance Efficiencies 4CareFusion Announces Departure of Chief Operating Officer 2
(Date:7/2/2015)... VA (PRWEB) , ... July 02, 2015 , ... sweetFrog ... Texas. The opening is now the 19th sweetFrog store located in the Lone Star ... list of fastest growing companies in 2014. , The store, which opened July 1 ...
(Date:7/2/2015)... ... ... swing, Americans are flocking to Canada’s many lakes to reel in their fair share of ... it’s easy to understand why. From the Pacific Northwest Coast of British Columbia to the ... huge industry, and Americans make up the vast majority of anglers from outside of Canada. ...
(Date:7/2/2015)... ... July 02, 2015 , ... Global leader and compression innovator, SIGVARIS ... for men. , For style that’s quick on its feet, men will love ... great news for men everywhere because a simple change in socks can dramatically help ...
(Date:7/2/2015)... TX (PRWEB) , ... July ... ... pressure wound therapy (NPWT) - pipeline review 2015” provides comprehensive information on ... of development. Complete report on negative pressure wound therapy (NPWT) with 22 ...
(Date:7/2/2015)... ... July 02, 2015 , ... Breakthrough technologies ... pain treatment. Dr. Lev Kalika, founder of New York Dynamic Neuromuscular Rehabilitation ... on the conservative treatment of back, hip, knee and shoulder pain as well ...
Breaking Medicine News(10 mins):Health News:sweetFrog Expands Texas Footprint with Location in Canton 2Health News:SIGVARIS Kicks Up Its Style for Men with the Launch of MIDTOWN MICROFIBER in a Dark Navy Stripe Pattern 2Health News:SIGVARIS Kicks Up Its Style for Men with the Launch of MIDTOWN MICROFIBER in a Dark Navy Stripe Pattern 3Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 4Health News:Breakthrough Technologies for Carpal Tunnel Treatment in New York City 2Health News:Breakthrough Technologies for Carpal Tunnel Treatment in New York City 3Health News:Breakthrough Technologies for Carpal Tunnel Treatment in New York City 4
... Calif., March 31 Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ... financing facility under which it may sell up to ... Ltd. over a,24-month period. Alexza is not obligated to ... to enter into and consummate other equity and,debt financing ...
... occur , , MONDAY, March 31 (HealthDay News) -- Cerebral ... from red blood cells that have leaked out of ... over age 60 than previously believed, according to a ... higher overall prevalence of cerebral microbleeds compared to other ...
... WILMINGTON, N.C., March 31 PPD, Inc. (Nasdaq:,PPDI) ... as executive,vice president of global clinical development. In ... company,s Phase II-IV operations in,North America; Latin America; ... "Mike Wilkinson brings an exceptional resume with strong ...
... A Saint Louis University cardiologist called upon the U.S. ... strong warning it recently placed on a diagnostic tool, ... life-threatening cardiac events. , In October 2007, the ... agents, which are used to improve the quality of ...
... following was,issued today by the National Press Club:, National ... 2:00 p.m., National Press Club (Broadcast Center), ... will discuss,Quality as a Path to Improving the Cost of ... patient safety and health care products and,services company, R. Kerry ...
... By Will Arnett, Matthew Broderick, Steve Carell, Stephen, ... Kevin James,Conan O,Brien, Rosie O,Donnell, Amy Poehler, Adam Sandler, ... The Insult Comic Dog And Many More To Be ... announced today that,Kelsey Grammer, Ben Stiller, Grammy Award-winning band ...
Cached Medicine News:Health News:Alexza Secures $50 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd. 2Health News:Alexza Secures $50 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd. 3Health News:Alexza Secures $50 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd. 4Health News:Small Brain Lesions More Common Than Thought in Those Over 60 2Health News:PPD Names Mike Wilkinson Executive Vice President of Global Clinical Development 2Health News:PPD Names Mike Wilkinson Executive Vice President of Global Clinical Development 3Health News:New research shows benefits of ultrasound contrast agents outweigh potential risk to heart patients 2Health News:New research shows benefits of ultrasound contrast agents outweigh potential risk to heart patients 3Health News:Kelsey Grammer, Ben Stiller, Maroon 5 and The Roots Added to COMEDY CENTRAL's(R) Live On-air Charity Special 'Night of Too Many Stars: An Overbooked Concert for Autism Education' Hosted by Jon Stewart on Sunday April 13, at 8 p.m. ET 2
Biotest ELPHA (=Enzyme Linked Probe Hybridization Assay) for class I and class II HLA typing shows convincing advantages for your lab routine....
This ELISA test is used for the detection and semi-quantitation of lgG antibobies to proteinase 3(pr3) in human sera, as an aid to the diagnosis of wegener s granulomatosis....
... for the semi-quantitative determination of specific ... serum. The results of the anti-GBM.assay ... in the diagnosis of diseases associated ... including Goodpastures Syndrome. Levels of these ...
The assay is an immunometric ('sandwich') EIA for the quantitative measurement of LH in human serum or plasma. LH in the sample is bound by 2 monoclonal anti-LH antibodies directed at different epito...
Medicine Products: